MC 02595

Drug Profile

MC 02595

Latest Information Update: 04 Oct 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Pharmaceutical; Essential Therapeutics [CEASED]
  • Class
  • Mechanism of Action Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pseudomonal infections

Most Recent Events

  • 04 Oct 2004 Discontinued - Preclinical for Pseudomonal infections in USA (unspecified route)
  • 06 May 2003 No development reported - Preclinical for Pseudomonal infections in USA (unspecified route)
  • 26 Sep 2000 Preclinical development for Pseudomonal infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top